Isabella C. Glitza Oliva, MD, PhD, MS

Peer-Reviewed Articles

1. Mattei J, Ruitao L, Davies MA, Wong MK, Diab A, Haydu LE, Patel SP, Amaria RN, McQuade JL, Tawbi H, Burton EM, Glitza IC. Adjuvant therapy in mucosal melanoma: a single-center experience and review of the literature. Melanoma Res 36(1):31-42, 2026. e-Pub 2026. PMID: 41337670.
2. Robert M, Saha S, Dizman N, Rohlfs M, Sirmans E, Simon J, Amaria RN, Glitza Oliva IC, Tawbi HA, Davies MA, Ikeguchi A, Basen-Engquist K, Schadler K, Roth ME, Song W, Zhang X, Ajami NJ, Cohen L, Wargo JA, Peterson CB, McQuade JL, Daniel CR. Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New Frontier. Nutrients 18(1), 2025. e-Pub 2025. PMID: 41515159.
3. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 15(12):2574, 2025. e-Pub 2025. PMID: 41327972.
4. Hasanov M, Kiany S, Forget MA, Bassett R, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Ross MI, Tawbi HA, Wargo JA, Wong MK, Bernatchez C, Hwu P, Haymaker C, Amaria RN. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology 14(1):2546402, 2025. e-Pub 2025. PMID: 40815607.
5. Dimitriou F, Wu X, Nagarajan P, Glitza IC, Zhao L, Ning J, Patel SP, Wargo JA, Futreal A, Woodman S, McQuade JL, Esmaeli B. Conjunctival melanoma genomic analysis reveals intermediate tumor mutation burden and genomic overlap with cutaneous melanoma. NPJ Precis Oncol 9(1):365, 2025. e-Pub 2025. PMID: 41261164.
6. Kimchi G, Varela S, Zuluaga-Garcia JP, Call-Orellana F, Ramirez Ferrer E, Andrade de Almeida RA, Gubbiotti MA, Glitza IC, Bishop AJ, Grant JD, North RY, Alvarez-Breckenridge CA, Rhines LD, Tatsui CE. Primary Intramedullary Spinal Melanocytomas: Case Report and Review of Clinical Features, Diagnosis, and Management. J Clin Med 14(22), 2025. e-Pub 2025. PMID: 41303082.
7. Borgers JSW, Johnson DB, Livingstone E, Schadendorf D, Buchbinder EI, Haydu LE, Gohil L, Robinson WA, Mehmi I, Hamid O, Ferreira M, Salama AKS, Dimitriou F, Carlino MS, Long GV, Ascierto PA, Simeone E, Najjar YG, Hospers GAP, Choi J, Chandra S, Wayne JD, Garcia CIR, Xu W, Lebbe C, Da-Meda L, Atkinson V, Mckean M, Forschner A, Asare EA, Daletzakis A, Taylor JS, Amant F, Tsai KK, Eroglu Z, Haanen JBAG, Glitza de Oliva IC. Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study. EClinicalMedicine 89:103501, 2025. e-Pub 2025. PMID: 41127564.
8. Guerrieri RA, Fischer GM, Cortez JR, Knighton BG, Ledesma DA, Hudgens CW, Delcid YF, Hu Q, Onana CYB, Carapeto FCL, Tezlaff MT, Huse JT, Hwu P, Burton EM, Glitza Oliva IC, Davies MA, Ferguson SD. Preclinical models of melanoma leptomeningeal disease to assess intrathecal checkpoint blockade. Sci Rep 15(1):34352, 2025. e-Pub 2025. PMID: 41038921.
9. Burton, EM, Milton, D, Tetzlaff, M, Wani, K, Ross, MI, Postow, MA, Segura Lazcano, R, Glitza, IC, Wong, MK, Patel, SP, Diab, A, Gershenwald, JE, McQuade, JL, Warner, AB, Prieto, V, Lee, JE, Goepfert, RP, Fisher, SB, Song, A, Malke, J, Simon, JM, Ariyan, C, Torres Cabala, CA, Davies, MA, Lazar, A, Wargo, J, Tawbi, H, Amaria, RN. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. Journal of Clinical Oncology 43(26):2856-2862, 2025. e-Pub 2025. PMID: 40638872.
10. Esmaeli, B, Ogden, T, Nichols, M, Lu, T, Debnam, JM, Dimitriou, F, McQuade, JL, Glitza, IC. Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma. Melanoma research 35(2):130-144, 2025. e-Pub 2025. PMID: 39656585.
11. Cottrell, T, Lotze, MT, Ali, A, Bifulco, C, Capitini, CM, Chow, LQ, Cillo, AR, Collyar, D, Cope, L, Deutsch, JS, Dubrovsky, G, Gnjatic, S, Goh, D, Halabi, S, Kohanbash, G, Maecker, HT, Maleki Vareki, S, Mullin, S, Seliger, B, Taube, JM, Vos, W, Yeong, J, Anderson, KG, Bruno, TC, Chiuzan, C, Diaz-Padilla, I, Garrett-Mayer, E, Glitza, IC, Grandi, P, Hill, EG, Hobbs, BP, Najjar, YG, Pettit Nassi, P, Simons, VH, Subudhi, SK, Sullivan, RJ, Takimoto, C. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols. Journal for immunotherapy of cancer 13(3), 2025. e-Pub 2025. PMID: 40054999.
12. Gouda, MA, Zarifa, A, Yang, Y, Stephen, B, Gurses, S, Sprenger, A, Tian, Y, Derbala, M, Glitza, IC, Meric-Bernstam, F, Patel, SP. Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma. Journal of Immunotherapy and Precision Oncology 8(1):82-88, 2025. e-Pub 2025. PMID: 39816915.
13. Glitza, IC, Palaia, J, Sakkal, LA, Patel, D, Moshyk, A, Han, N, Odak, S, Schmier, JK, Ning, N, Chandra, S. Real-world outcomes in patients with melanoma brain metastasis. BMJ open 15(1), 2025. e-Pub 2025. PMID: 39890146.
14. Gouda MA, Stephen B, Tian Y, Alshawa A, Onwugaje DOC, Albittar A, Yang Y, Zarifa A, Yilmaz B, Gurses S, Sprenger A, Derbala MH, Brink A, How JA, Moyers J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Patel SP, Oliva IG. A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. J Immunother Precis Oncol, 2024. e-Pub 2024. PMID: 39524469.
15. Keatts SA, Salem AF, Swanson DM, Farooqi AS, Bishop AJ, Amaria RN, McQuade JL, Glitza Oliva IC, Diab A, Weiser R, Fisher SB, Goepfert RP, Ross MI, Ashleigh Guadagnolo B, Mitra D. Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma. Clin Transl Radiat Oncol 49:100856, 2024. e-Pub 2024. PMID: 39308633.
16. Saberian, C, Milton, D, Simon, JM, Amaria, RN, Diab, A, McQuade, JL, Patel, SP, Tawbi, H, Yee, C, Wong, MK, McCutcheon, IE, Davies, MA, Ferguson, SD, Glitza, IC. Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma. Neuro-Oncology Practice 11(4):452-463, 2024. e-Pub 2024. PMID: 39006528.
17. Kumthekar, P, Schwartz, M, Nagpal, S, Glitza, IC, Forsyth, P, Gormley, W, Patel, R, Glicksman, MA, Sonabend, AM. Novel non-invasive method for measuring intracranial pressure for drug delivery and other neurologic disorders. Journal of Clinical Oncology 42(16):2031, 2024. e-Pub 2024.
18. Beckham, TH, Dudzinski, SO, Pasli, M, Perni, S, Tom, MC, Ghia, AJ, Yeboa, DN, McAleer, MF, Swanson, T, McGovern, SL, Wang, C, Chung, C, Briere, TM, An, R, De, BS, Glitza, IC, Kim, YB, McCutcheon, IE, Ferguson, SD, Li, J. Radiosurgery to 5 or more newly diagnosed brain metastases in the systemic therapy era. Journal of Clinical Oncology 42(16):2026, 2024. e-Pub 2024.
19. E. Burton, V. Honaker, D. Milton, I. Glitza, R. Amaria, S. Patel, A. Diab, M. Wong, J. McQuade, C. Chung, J. Wefel, J. Li, M. Davies, H. Tawbi. Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM). EJC Skin Cancer 2, 2024. e-Pub 2024.
20. Antonio Pizuorno Machado, Abdullah Salim Shaikh, Alice Saji, Malek Shatila, Glitza Oliva IC, Yinghong Wang, Anusha Shirwaikar Thomas. Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with Cancer, 2024. e-Pub 2024. PMID: 38791997.
21. Glitza IC, Seo YD, Spencer CN, Wortman JR, Burton EM, Alayli FA, Loo CP, Gautam S, Damania A, Densmore J, Fairchild J, Cabanski CR, Wong MC, Peterson CB, Weiner B, Hicks N, Aunins JG, McChalicher C, Walsh E, Tetzlaff MT, Hamid O, Ott PA, Boland GM, Sullivan RJ, Grossmann KF, Ajami NJ, LaVallee T, Henn MR, Tawbi HA, Wargo JA. Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. Cancer Discov 14(7):OF1-OF15, 2024. e-Pub 2024. PMID: 38588588.
22. Nelson BE, Roszik J, Ahmed J, Barretto CMN, Nardo M, Campbell E, Johnson AM, Piha-Paul SA, Oliva ICG, Weathers SP, Cabanillas M, Javle M, Meric-Bernstam F, Subbiah V. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. Mol Cancer, 2024. PMID: 38532456.
23. Jacques, SK, McKeown, J, Grover, P, Johnson, DB, Zaremba, A, Dimitriou, F, Weiser, R, Farid, M, Namikawa, K, Sullivan, RJ, Rutkowski, P, Lebbé, C, Hamid, O, Zager, JS, Michielin, O, Neyns, B, Nakamura, Y, Robert, C, Mehnert, JM, Ascierto, PA, Bhave, P, Park, B, Zimmer, L, Mangana, J, Mooradian, M, Placzke, J, Allayous, C, Glitza, IC, Mehmi, I, Depalo, D, Wicky, A, Schwarze, JK, Roy, S, Boatwright, C, Vanella, V, Long, GV, Menzies, AM, Lo, S, Carlino, MS. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy. European Journal of Cancer 199, 2024. e-Pub 2024. PMID: 38278007.
24. Huntoon, K, Gasco, J, Glitza, IC, Ferguson, SD, Majd, NK, McCutcheon, IE. Ventriculoperitoneal shunting with an on–off valve for patients with leptomeningeal metastases and intracranial hypertension. Neuro-Oncology Practice 11(1):56-63, 2024. e-Pub 2024. PMID: 38222058.
25. Kuang, AG, Mohajir, W, Panneerselvam, K, McQuade, JL, Glitza, IC, Khan, MA, Zhang, HC, Thomas, AS, Wang, Y. Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy. Annals of Gastroenterology 36(1):45-53, 2023. e-Pub 2023. PMID: 36593813.
26. Nardo M, Yilmaz B, Nelson BE, Torres HA, Wang LS, Granwehr BP, Song J, Dalla Pria HRF, Trinh VA, Glitza Oliva IC, Patel SP, Tannir NM, Kaseb AO, Altan M, Lee SS, Miller E, Zhang H, Stephen BA, Naing A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist 28(8):714-721, 2023. e-Pub 2023. PMID: 36952233.
27. Pizuorno Machado A, Shatila M, Liu C, Lu Y, Altan M, Glitza Oliva IC, Zhao D, Zhang HC, Thomas A, Wang Y. Characteristics, treatment, and outcome of patients with bowel perforation after immune checkpoint inhibitor exposure. J Cancer Res Clin Oncol 149(9):5989-5998, 2023. e-Pub 2023. PMID: 36611109.
28. Pizuorno Machado A, Shatila M, Glitza Oliva IC, Altan M, Siddiqui B, Zhou Y, Varatharajalu K, Zhang HC, Thomas A, Wang Y. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment. Am J Clin Oncol 46(8):360-365, 2023. e-Pub 2023. PMID: 37219360.
29. Hasanov M, Milton DR, Bea Davies A, Sirmans E, Saberian C, Posada EL, Opusunju S, Gershenwald JE, Torres-Cabala CA, Burton EM, Colen R, Huse JT, Glitza Oliva IC, Chung C, McAleer MF, McGovern SL, Yeboa DN, Kim BYS, Prabhu SS, McCutcheon IE, Weinberg J, Lang FF, Tawbi HA, Li J, Haydu LE, Davies MA, Ferguson SD. Changes In Outcomes And Factors Associated With Survival In Melanoma Patients With Brain Metastases. Neuro Oncol 25(7):1310-1320, 2023. e-Pub 2022. PMID: 36510640.
30. Steininger J, Gellrich FF, Engellandt K, Meinhardt M, Westphal D, Beissert S, Meier F, IC . Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment. Int J Mol Sci 24(14), 2023. e-Pub 2023. PMID: 37511202.
31. Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Burton EM, Tawbi HA, Davies MA. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med 29(4):898-905, 2023. e-Pub 2023. PMID: 36997799.
32. Jeun R, Iyer PC, Best C, Lavis V, Varghese JM, Yedururi S, Brady V, Glitza Oliva IC, Dadu R, Milton DR, Brock K, Thosani S. Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center. Immunotherapy 15(6):417-428, 2023. e-Pub 2023. PMID: 37013834.
33. Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature, 2023. e-Pub 2023.
34. Kuang AG, Mohajir W, Panneerselvam K, McQuade JL, Oliva ICG, Khan MA, Zhang HC, Thomas AS, Wang Y. Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy. Ann Gastroenterol, 2023. e-Pub 2023.
35. Kim, ST, Chu, Y, Misoi, MW, Suarez-Almazor, M, Tayar, JH, Lu, H, Buni, M, Kramer, J, Rodriguez, E, Hussain, Z, Neelapu, SS, Wang, J, Shah, AY, Tannir, NM, Campbell, M, Gibbons, DL, Cascone, T, Lu, C, Blumenschein, GR, Altan, M, Lim, B, Valero, V, Loghin, ME, Tu, J, Westin, SN, Naing, A, Garcia-Manero, G, Hassan, NA, Tawbi, H, Hwu, P, Glitza, IC, Davies, MA, Patel, SP, Zou, J, Futreal, A, Diab, A, Wang, L, Nurieva, R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature communications 13(1), 2022. e-Pub 2022. PMID: 35413951.
36. Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 611(7934):155-160, 2022. e-Pub 2022. PMID: 36289334.
37. Mathew A, Shatila M, Lai Z, Tan D, Glitza Oliva IC, Wang J, Alhalabi O, Zhang HC, Thomas A, Wang Y. Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients. Journal of Cancer Research and Clinical Oncology 149(8):4591-4599, 2022. e-Pub 2022. PMID: 36163559.
38. Vasavada S, Panneerselvam K, Amin R, Varatharajalu K, Okhuysen PC, Oliva ICG, Wang J, Grivas P, Thomas AS, Wang Y. Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors. Ann Gastroenterol 35(4):393-399, 2022. e-Pub 2022. PMID: 35784625.
39. Creasy CA, Meng YJ, Forget MA, Karpinets T, Tomczak K, Stewart C, Torres-Cabala CA, Pilon-Thomas S, Sarnaik AA, Mule JJ, Garraway L, Bustos M, Zhang J, Patel SP, Diab A, Glitza IC, Yee C, Tawbi H, Wong MK, McQuade J, Hoon DSB, Davies MA, Hwu P, Amaria RN, Haymaker C, Beroukhim R, Bernatchez C. Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res 28(9):1911-1924, 2022. e-Pub 2022. PMID: 35190823.
40. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 1:1970, 2022. e-Pub 2022.
41. Patel AB, Farooq S, Welborn M, Amaria RN, Chon SY, Diab A, Glitza Oliva IC, Huen AO, Li SQ, Nelson KC, Pacha O, Patel SP, Rapini RP, Tawbi HA, Wong MK, McQuade J, Davies MA, Haydu LE. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer 128(5):975-983, 2022. e-Pub 2021. PMID: 34724197.
42. Giubellino A, Nelson AC, He Y, Munro SA, Song KY, Glitza Oliva IC, Torres-Cabala C. Molecular characterization of biphenotypic epithelioid and plexiform melanoma with deep penetrating nevus-like features. Pigment Cell Melanoma Res 35(2):229-237, 2022. e-Pub 2021. PMID: 34633770.
43. Starling, Caroline T, Messer, Alison A, Kleiman, Anne, McQuade, Jennifer L, Glitza, Isabella C, Torres-Cabala, Antonio C, Heberton, Meghan. Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab. Dermatology Online Journal, 2022. e-Pub 2022.
44. Starling, CT, Messer, A, Kleiman, A, McQuade, JL, Glitza, IC, Torres Cabala, CA, Heberton, MM. Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab. Dermatology online journal 28(2), 2022. e-Pub 2022. PMID: 35670686.
45. Steininger, J, Oliva G, IC IC. Current therapeutic approaches in malignant melanoma patients with leptomeningeal disease. Best Practice Onkologie(17):96-102, 2022. e-Pub 2022.
46. Piña Y, Yadugiri S, Yeboa DN, Ferguson SD, Forsyth PA, Oliva ICG. Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma. Curr Oncol Rep 24(1):43-54, 2022. e-Pub 2022. PMID: 35059999.
47. Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P, Amaria RN. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Front Oncol 12:1001150, 2022. e-Pub 2022. PMID: 36324592.
48. Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575):1632-1640, 2021. e-Pub 2021. PMID: 34941392.
49. Zou F, Faleck D, Thomas A, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer S, McQuade J, Obeid M, Shah A, Richards DM, Sharon E, Wolchok J, Thompson J, Wang Y. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 9(11), 2021. e-Pub 2021. PMID: 34789551.
50. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol 162:60-67, 2021. e-Pub 2021. PMID: 34237343.
51. Aaroe AE, Glitza Oliva IC, Al-Zubidi N, Nader ME, Kaya D, Ferguson SD, Wang C, Fuller G, Harrison RA. Pearls & Oy-sters: Primary Pineal Melanoma With Leptomeningeal Carcinomatosis. Neurology 97(5):248-250, 2021. e-Pub 2021. PMID: 33931525.
52. Jacob JS, Dutra BE, Garcia-Rodriguez V, Panneerselvam K, Abraham FO, Zou F, Ma W, Grivas P, Thompson JA, Altan M, Oliva ICG, Zhang HC, Thomas AS, Wang Y. Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. J Natl Compr Canc Netw 19(12):1415-1424, 2021. e-Pub 2021. PMID: 34348238.
53. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med 27(8):1432-1441, 2021. e-Pub 2021. PMID: 34239137.
54. Zou F, Abu-Sbeih H, Ma W, Peng Y, Qiao W, Wang J, Shah AY, Glitza Oliva IC, Piha-Paul SA, Thompson JA, Zhang HC, Thomas AS, Wang Y. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. J Natl Compr Canc Netw 19(6):1-9, 2021. e-Pub 2020. PMID: 33316767.
55. Saberian C, Amaria RN, Najjar AM, Radvanyi LG, Haymaker CL, Forget MA, Bassett RL, Faria SC, Glitza IC, Alvarez E, Parshottam S, Prieto V, Lizée G, Wong MK, McQuade JL, Diab A, Yee C, Tawbi HA, Patel S, Shpall EJ, Davies MA, Hwu P, Bernatchez C. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer 9(5), 2021. e-Pub 2021. PMID: 34021033.
56. Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, Diab A, Ekmekcioglu S, Wong MK, Davies MA, Amaria RN. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med 10(7):2293-2299, 2021. e-Pub 2021. PMID: 33686688.
57. Zou F, Wang X, Glitza IC, McQuade JL, Wang J, Zhang HC, Thompson JA, Thomas AS, Wang Y. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer 9(1), 2021. e-Pub 2021. PMID: 33436487.
58. Najem H, Marisetty A, Horbinski C, Long J, Huse JT, Glitza Oliva IC, Ferguson SD, Kumthekar PU, Wainwright DA, Chen P, Lesniak MS, Burks JK, Heimberger AB. CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Front Immunol 12:745893, 2021. e-Pub 2021. PMID: 34691054.
59. Marques-Piubelli ML, Tetzlaff MT, Nagarajan P, Duke TC, Glitza IC, Ledesma DA, Aung PP, Torres-Cabala CA, Wistuba II, Prieto VG, Nelson KC, Curry JL. Hypertrophic Lichenoid Dermatitis Immune-Related Adverse Event During Combined Immune Checkpoint and Exportin Inhibitor Therapy: A Diagnostic Pitfall for Superficially Invasive Squamous Cell Carcinoma. J Cutan Pathol 47(10):954-959, 2020. e-Pub 2020. PMID: 32394425.
60. Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, Chen D, Masrorpour F, Li A, Hong DS, Diab A, Nguyen QN, Glitza IC, Ferrarotto R, Chun SG, Cortez MA, Welsh J. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33106386.
61. Giridharan N, Glitza Oliva IC, O'Brien BJ, Parker Kerrigan BC, Heimberger AB, Ferguson SD. Targeting the Tumor Microenvironment in Brain Metastasis. Neurosurg Clin N Am 31(4):641-649, 2020. e-Pub 2020. PMID: 32921358.
62. Bucheit AD, Hardy JT, Szender JB, Glitza IC. Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition. Melanoma Res 30(4):423-425, 2020. e-Pub 2020. PMID: 32073510.
63. Messer A, Drozd B, Glitza IC, Lu H, Patel AB. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature. Dermatol Online J 26(8), 2020. e-Pub 2020. PMID: 32941716.
64. Glitza IC, Smalley KSM, Brastianos PK, Davies MA, McCutcheon I, Liu JKC, Ahmed KA, Arrington JA, Evernden BR, Smalley I, Eroglu Z, Khushalani N, Margolin K, Kluger H, Atkins MB, Tawbi H, Boire A, Forsyth P. Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell Melanoma Res 33(4):527-541, 2020. e-Pub 2020. PMID: 31916400.
65. Bastos DCA, Rao G, Oliva ICG, Loree JM, Fuentes DT, Stafford RJ, Beechar VB, Weinberg JS, Shah K, Kumar VA, Prabhu SS. Predictors of Local Control of Brain Metastasis Treated With Laser Interstitial Thermal Therapy. Neurosurgery 87(1):112-122, 2020. e-Pub 2020. PMID: 31539421.
66. Hong BY, Ford JR, Glitza IC, Torres Cabala CA, Tetzlaff M, Prieto VG, Parker R, Daniel C, Esmaeli B. Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma. Ophthalmic Plast Reconstr Surg 37(1):E9-E13. e-Pub 2020. PMID: 32618825.
67. Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol 38(13):JCO1901508, 2020. e-Pub 2020. PMID: 31990608.
68. Glitza IC, Tawbi HA. "Liquid Gold"- The unTAPped potential of cerebrospinal fluid analysis?. Clin Cancer Res 26(9):2083-2084, 2020. e-Pub 2020. PMID: 32139404.
69. Lucci, A, Hall, CS, Patel, SP, Narendran, B, Bauldry, JB, Royal, RE, Karhade, M, Upshaw, J, Wargo, J, Glitza, IC, Wong, MK, Amaria, RN, Tawbi, H, Diab, A, Davies, MA, Gershenwald, JE, Lee, JE, Hwu, P, Ross, MI. Circulating tumor cells and early relapse in node-positive melanoma. Clinical Cancer Research 26(8):1886-1895, 2020. e-Pub 2020. PMID: 32015020.
70. Safa H, Bhosale P, Weissferdt A, Glitza IC. Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma. Immunotherapy 12(5):293-298, 2020. e-Pub 2020. PMID: 32295435.
71. Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MI. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Research 26(8):1895-1896, 2020. e-Pub 2020.
72. Holbrook K, Lutzky J, Davies MA, Davis JM, Glitza IC, Amaria RN, Diab A, Patel SP, Amin A, Tawbi H. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer 126(3):523-530, 2020. e-Pub 2020. PMID: 31658370.
73. Schvartsman G, Ma J, Bassett RL, Haydu LE, Amaria RN, Hwu P, Wong MK, Hwu WJ, Diab A, Patel SP, Davies MA, Hamerschlak N, Tawbi HA, Glitza Oliva IC. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer 125(23):4193-4202, 2019. e-Pub 2019. PMID: 31398264.
74. Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI, Cortez MA, Erasmus JJ, de Groot P, Carter BW, Hong DS, Glitza IC, Ferrarotto R, Altan M, Diab A, Chun SG, Heymach JV, Tang C, Nguyen QN, Welsh JW. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer 7(1):237, 2019. e-Pub 2019. PMID: 31484556.
75. Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SMA, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM, Long GV, Johnson DB, Menzies AM. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell Melanoma Res 32(4):553-563, 2019. e-Pub 2019. PMID: 30767428.
76. Ferguson SD, Bindal S, Bassett RL, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza IC. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol 142(3):499-509, 2019. e-Pub 2019. PMID: 30847840.
77. Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov 9(5):628-645, 2019. e-Pub 2019. PMID: 30787016.
78. Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res 32(3):458-469, 2019. e-Pub 2019. PMID: 30712316.
79. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 7(1):107, 2019. e-Pub 2019. PMID: 30995944.
80. Sprouse ML, Welte T, Boral D, Liu HN, Yin W, Vishnoi M, Goswami-Sewell D, Li L, Pei G, Jia P, Glitza-Oliva IC, Marchetti D. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling. Int J Mol Sci 20(8), 2019. e-Pub 2019. PMID: 31003475.
81. Safa H, Glitza Oliva IC. Cardiac Metastases in Melanoma. N Engl J Med 380(9):858, 2019. e-Pub 2019. PMID: 30811912.
82. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1941, 2018. e-Pub 2018. PMID: 30361511.
83. Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of Brain Metastases: Prioritization of Therapeutic Targets. Int J Cancer 143(11):3019-3026, 2018. e-Pub 2018. PMID: 29923182.
84. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 2018. e-Pub 2018. PMID: 30297909.
85. Glitza, IC, Rohlfs, ML, Iqbal, M, Richard, J, Burton, EM, Duncan, S, Brown, C, Anderson, JE, Hwu, P, Hwu, WJ, Wong, MK, Yee, C, Patel, SP, Woodman, SE, Amaria, RN, Diab, A, Tawbi, H, Davies, MA. A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD). Annals of oncology : official journal of the European Society for Medical Oncology 29:viii464, 2018. e-Pub 2018. PMID: 32137192.
86. Chen WS, Tetzlaff MT, Diwan H, Jahan-Tigh R, Diab A, Nelson K, Glitza IC, Kaunitz GJ, Johnson D, Torres-Cabala C, Pacha O, Taube JM, Maloney K, Prieto VG, Curry JL. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. J Cutan Pathol 45(10):764-773, 2018. e-Pub 2018. PMID: 29943453.
87. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 6(1):103, 2018. e-Pub 2018. PMID: 30305177.
88. Vishnoi M, Boral D, Liu H, Sprouse ML, Yin W, Goswami-Sewell D, Tetzlaff MT, Davies MA, Glitza IC, Marchetti D. Targeting USP7 identifies a metastasis-compotent state within bone marrow-resident melanoma CTCs. Cancer Research 78(18):5249-5262, 2018. e-Pub 2018. PMID: 30026332.
89. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. PMID: 29848573.
90. Glitza IC, Reddy ST, Patel SP. Leptomeningeal disease in uveal melanoma: a case series. J Neurooncol 139(2):503-505, 2018. e-Pub 2018. PMID: 29704079.
91. Ballester LY, Glitza IC, Douse DY, Chen MM, Lan C, Haydu LE, Huse JT, Roy-Chowdhuri S, Luthra R, Wistuba II, Davies MA. Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients with Melanoma and Leptomeningeal Disease. J Neuropathol Exp Neurol 77(7):628-635, 2018. e-Pub 2018. PMID: 29873738.
92. Trinidad C, Nelson KC, Glitza IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. J Cutan Pathol 45(7):504-507, 2018. e-Pub 2018. PMID: 29633300.
93. Glitza IC, Schvartsman G, Tawbi H. Advances in the systemic treatment of melanoma brain metastases. Ann Oncol 29(7):1509-1520, 2018. e-Pub 2018. PMID: 29790899.
94. Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F. Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers. Mol Cancer Ther 17(3):671-676, 2018. e-Pub 2018. PMID: 29237802.
95. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomized, phase 2 trial. Lancet Oncol 19(2):181-193, 2018. e-Pub 2018. PMID: 29361468.
96. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2018. PMID: 29097493.
97. Glitza IC, Alqusairi R. Immunotherapy for Melanoma. Adv Exp Med Biol 995:43-63, 2018. e-Pub 2018. PMID: 30539505.
98. Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3(1):e000283, 2018. e-Pub 2018. PMID: 29387478.
99. Glitza IC, Guha-Thakurta N, D'Souza NM, Amaria RN, McGovern SL, Rao G, Li J. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases. Melanoma Res 27(6):580-584, 2017. e-Pub 2017. PMID: 28817446.
100. An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, |Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 125(1):80-88, 2017. e-Pub 2017. PMID: 28916225.
101. Glitza IC, Bucheit A. Clinical Response of Central Nervous System Melanoma to Anti-PD1 Therapy in 2 Melanoma Patients. Scientific Journal of Immunology, 2017. e-Pub 2017.
102. Fang P, Jiang W, Glitza IC, Guha N, Hwu P, Phan J, Mahajan A, Tawbi H, Li J. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment on intracranial disease in metastatic melanoma. J Neurooncology 133(3):595-602, 2017. e-Pub 2017. PMID: 28500560.
103. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. e-Pub 2017. PMID: 28251903.
104. Chakravarti N, Ivan D, Trinh VA, Glitza IC, Curry JL, Torres-Cabala C, Tetzlaff MT, Bassett RL, Prieto VG, Hwu WJ. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. Melanoma Res 27(1):24-31, 2017. e-Pub 2017. PMID: 27768639.
105. Glitza IC, Tawbi H, Davies MA. Melanoma Brain Metastases: Current Areas of Investigation and Future Directions. Cancer J 23(1):68-74, 2017. e-Pub 2017. PMID: 28114258.
106. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2(1), 2017. e-Pub 2017. PMID: 28819565.
107. Jour G, Glitza IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, Nagarajan P, Huen A, Aung PP, Ivan D, Drucker CR, Prieto VG, Rapini RP, Patel A, Curry JL. Autoimmune Dermatologic Toxicities from Immune Checkpoint Blockade with anti-PD-1 Antibody Therapy: A Report on Bullous Skin Eruptions. J Cutan Pathol 43(8):688-96, 2016. e-Pub 2016. PMID: 27086658.
108. Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol 2(8):1056-64, 2016. e-Pub 2016. PMID: 27124486.
109. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. PMID: 27301722.
110. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
111. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6(2):202-16, 2016. e-Pub 2016. PMID: 26645196.
112. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology, 2016. e-Pub 2016.
113. Glitza IC, Haymaker C, Bernatchez C, Vence L, Rohlfs M, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Patel SP, Woodman SE, Hwu WJ, Radvanyi LG, Davies MA, Papadopoulos NE, Hwu P. Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: A case report. Cancer Immunol Res 3(11):1201-6, 2015. e-Pub 2015. PMID: 26216417.
114. Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH. Chromosome 8q24.1/c-MYC Abnormality: A Marker for High-Risk Myeloma. Leuk Lymphoma 56(3):1-18, 2015. e-Pub 2015. PMID: 24844357.
115. Glitza IC, Davies MA. Genotyping of cutaneous melanoma. Chin Clin Oncol 3(3):1-16, 2014. e-Pub 2014. PMID: 25632386.
116. Lu G, Muddasani R, Orlowski RZ, Abruzzo LV, Qazilbash MH, You MJ, Wang Y, Zhao M, Chen S, Glitza IC, Medeiros LJ. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med 137(5):625-31, 2013. e-Pub 2013. PMID: 23627452.
117. Hui D, Glitza I, Chisholm G, Yennu S, Bruera E. Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials. Cancer 119(5):1098-105, 2013. e-Pub 2013. PMID: 23132290.
118. Glitza IC, Ehrhard I, Müller-Pebody B, Reintjes R, Breuer T, Ammon A, Sonntag HG. Longitudinal study of meningococcal carrier rates in teenagers. Int J Hyg Environ Health 211(3-4):263-72, 2008. e-Pub 2008. PMID: 17981083.

Review Articles

1. Wilcox JA, Chukwueke UN, Ahn MJ, Aizer AA, Bale TA, Brandsma D, Brastianos PK, Chang S, Daras M, Forsyth P, Garzia L, Glantz M, Oliva ICG, Kumthekar P, Le Rhun E, Nagpal S, O'Brien B, Pentsova E, Lee EQ, Remsik J, Ruda R, Smalley I, Taylor MD, Weller M, Wefel J, Yang JT, Young RJ, Wen PY, Boire AA. Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions. Neuro Oncol 26(10):1781-1804, 2024. e-Pub 2024. PMID: 38902944.
2. Smalley, I, Boire, A, Brastianos, PK, Kluger, H, Hernando-Monge, E, Forsyth, P, Ahmed, KA, Smalley, KS, Ferguson, SD, Davies, MA, Glitza, IC. Leptomeningeal disease in melanoma. Pigment Cell and Melanoma Research 37(1):51-67, 2024. e-Pub 2024. PMID: 37622466.
3. Kim, MM, Mehta, MP, Smart, DD, Steeg, PS, Hong, JA, Espey, MG, Prasanna, P, Crandon, L, Hodgdon, C, Kozak, N, Armstrong, TS, Morikawa, A, Willmarth, N, Tanner, K, Boire, A, Hayden Gephart, MG, Margolin, K, Hattangadi-Gluth, J, Tawbi, H, Trifiletti, DM, Chung, C, Basu-Roy, U, Burns, R, Glitza, IC, Aizer, A, Anders, CK, Davis, J, Ahluwalia, MS, Chiang, V, Li, J, Kotecha, R, Formenti, SC, Ellingson, BM, Gondi, V, Sperduto, PW, Barnholtz-Sloan, J, Rodon Ahnert, J, Lee, EQ, Khasraw, M, Yeboa, DN, Brastianos, PK, Galanis, E, Coleman, CN, Ahmed, MM. National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research. The lancet oncology 24(8):e344-e354, 2023. e-Pub 2023. PMID: 37541280.
4. Karz A, Dimitrova M, Kleffman K, Alvarez-Breckenridge C, Atkins MB, Boire A, Bosenberg M, Brastianos P, Cahill DP, Chen Q, Ferguson S, Forsyth P, Glitza Oliva IC, Goldberg SB, Holmen SL, Knisely JPS, Merlino G, Nguyen DX, Pacold ME, Perez-Guijarro E, Smalley KSM, Tawbi HA, Wen PY, Davies MA, Kluger HM, Mehnert JM, Hernando E. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res 35(6):554-572, 2022. e-Pub 2022. PMID: 35912544.
5. Steininger, J, Glitza, IC. Aktuelle Therapieansätze beim malignen Melanom mit leptomeningealer Metastasierung. Best Practice Onkologie 17(3):96-102, 2022. e-Pub 2022.
6. Ferguson SD, Fomchenko EI, Guerrieri RA, Glitza Oliva IC. Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD). Front Oncol 11:800053, 2021. e-Pub 2021. PMID: 35096602.
7. Amaria, RN, Menzies, AM, Burton, EM, Scolyer, RA, Tetzlaff, M, Antdbacka, R, Ariyan, C, Bassett Jr, R, Carter, B, Daud, AI, Faries, MB, Fecher, LA, Flaherty, KT, Gershenwald, JE, Hamid, O, Hong, A, Kirkwood, JM, Lo, S, Margolin, K, Messina, JL, Postow, MA, Rizos, H, Ross, MI, Rozeman, EA, Saw, RP, Sondak, V, Sullivan, RJ, Taube, JM, Thompson, JF, Van De Wiel, BA, Eggermont, AM, Davies, MA, Andrews, MC, Berry, D, Block, MS, Boland, GM, Bollin, KB, Carlino, MS, Carvajal, R, Cohen, JB, Davar, D, Delman, KA, Dummer, R, Farwell, MD, Fisher, DE, Fusi, A, Glitza, IC, de Gruijl, T, Gyorki, DE, Hauschild, A, Hieken, TJ, Larkin, J, Lawson, DH, Lebbé, C, Lee, JE, Lowe, MC, Luke, JJ, McArthur, GA, McDermott, DF, McQuade, JL, Gangadhar, TC, Petrella, T, Prieto, PA, Puzanov, I, Robert, C, Salama, A, Sandhu, S, Schadendorf, D, Shoushtari, AN, Sosman, JA, Swetter, S, Tanabe, KK, Turajlic, S, Tyler, DS, Woodman, SE, Wright, F, Zager, JS, Ascierto, PA, Spillane, A, Van Akkooi, AC, Wargo, J, Blank, CU, Tawbi, H, Long, GV. Neoadjuvant systemic therapy in melanoma. The Lancet Oncology 20(7):e378-e389, 2019. e-Pub 2019. PMID: 31267972.
8. Schvartsman G, Taranto P, Glitza IC, Agarwala SS, Atkins MB, Buzaid AC. Management of metastatic cutaneous melanoma: updates in clinical practice. Ther Adv Med Oncol 11:1758835919851663, 2019. e-Pub 2019. PMID: 31205512.
9. Kuske M, Rauschenberg R, Garzarolli M, Meredyth-Stewart M, Beissert S, Troost EGC, Glitza IC, Meier F. Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges. Am J Clin Dermatol 19(4):529-541, 2018. e-Pub 2018. PMID: 29417399.
10. Westphal D, Glitza IC, Niessner H. Molecular insights into melanoma brain metastases. Cancer 123(S11):2163-2175, 2017. e-Pub 2017. PMID: 28543697.
11. Cox VL, Bhosale P, Varadhachary GR, Wagner-Bartak N, Glitza IC, Gold KA, Atkins JT, Soliman PT, Hong DS, Qayyum A. Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. Radiology 283(2):314-340, 2017. e-Pub 2017. PMID: 28418819.
12. Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Melanoma Central Nervous System Metastases: Current Approaches, Challenges, and Opportunities. Pigment Cell Melanoma Res 29(6):627-642, 2016. e-Pub 2016. PMID: 27615400.

Other Articles

1. Glitza, IC Intrathecal Immunotherapy in Patients Who Have Melanoma With Leptomeningeal Disease. Clinical Advances in Hematology and Oncology 23(4):204-206, 2025. PMID: 40590875.
2. Glitza, IC, Ferguson, SD, Bassett Jr, R, Foster, AP, John, I, Hennegan, TD, Rohlfs, ML, Richard, J, Iqbal, M, Dett, TK, Lacey, C, Jackson, N, Rodgers, TE, Phillips, S, Duncan, S, Haydu, LE, Lin, R, Amaria, RN, Wong, MK, Diab, A, Yee, C, Patel, SP, McQuade, JL, Fischer, G, McCutcheon, IE, O'Brien, BJ, Tummala, S, Debnam, M, Guha-Thakurta, N, Wargo, J, Carapeto, F, Hudgens, CW, Huse, J, Tetzlaff, M, Burton, EM, Tawbi, H, Davies, MA Author Correction. Nature medicine 30(6):1787, 2024. PMID: 38649781.
3. Amaria, RN, Postow, MA, Burton, EM, Tetzlaff, M, Ross, MI, Torres Cabala, CA, Glitza, IC, Duan, F, Milton, D, Busam, KJ, Simpson, LM, McQuade, JL, Wong, MK, Gershenwald, JE, Lee, JE, Goepfert, RP, Keung, EZ, Fisher, SB, Betof Warner, A, Shoushtari, AN, Callahan, MK, Coit, D, Bartlett, E, Bello, DM, Momtaz, P, Nicholas, C, Gu, A, Zhang, X, Rao Korivi, B, Patnana, M, Patel, SP, Diab, A, Lucci, A, Prieto, V, Davies, MA, Allison, JP, Sharma, P, Wargo, J, Ariyan, C, Tawbi, H Author Correction. Nature 615(7953):E23, 2023. PMID: 36894629.
4. Amaria, RN, Reddy, S, Tawbi, H, Davies, MA, Ross, MI, Glitza, IC, Cormier, JN, Lewis, CM, Hwu, W, Hanna, EY, Diab, A, Wong, MK, Royal, RE, Gross, N, Weber, RS, Lai, SY, Ehlers II, RA, Blando, J, Milton, D, Woodman, SE, Kageyama, R, Wells, DK, Hwu, P, Patel, SP, Lucci, A, Hessel, AC, Lee, JE, Gershenwald, JE, Simpson, LM, Burton, EM, Posada, LP, Haydu, LE, Wang, L, Zhang, S, Lazar, A, Hudgens, CW, Gopalakrishnan, V, Reuben, A, Andrews, MC, Spencer, C, Prieto, V, Sharma, P, Allison, JP, Tetzlaff, M, Wargo, J Erratum. Nature medicine 24(12):1941, 2018. PMID: 30361510.

Editorials

1. Najjar, YG, Orloff, M, Mitchell, TC, Bowles, TL, Warner, AB, Bollin, KB, Chandra, S, Cohen, JV, Eroglu, Z, Funchain, P, Gaughan, EM, Glitza, IC, Hsu, S, Hu-Lieskovan, S, Kennedy, LB, Truong, TG, McKean, M, Mehnert, JM, Moon, H, Tsai, KK, Wilson, MA, Tran, T, Buchbinder, E, Fecher, LA, Guild, SR, Patel, SP. Proceedings of the seventh annual Women in Melanoma Conference. Therapeutic Advances in Medical Oncology 17, 2025. PMID: 40535733.

Abstracts

1. Montazari EJ, Abdel-Wahab N, Johnson DH, Amaria RN, McVay KK, Spillson CA, S-E B, Glitza Oliva IC, Patel S, Awiwi MO, Hassan A, Tahon N, Elsayes KM, Altan M, Wong M, McQuade J, Tawbi H, Davies MA, Yee C, Ekmekcioglu S, Zhang Y, Duan F, Yadav SS, Basu S, Allison J, Sharma P, Diab A. Clinical outcome and preliminary immune analysis of phase II clinical trial of combination of tocilizumab with ipilimumab and nivolumab for patients with treatment naive metastatic melanoma. 2023 ESMO Immuno-Oncology, Geneva, Switzerland, 2023. e-Pub 2023.
2. Abdel-Wahab N, Johnson DH, Amaria RN, Montazari EJ, McVay KK, Spillson CA, S-E B, Oliva ICG, Patel S, Awiwi MO, Hassan A, Tahon N, Elsayes KM, Wong M, McQuade J, Tawbi H, Davies MA, Yee C, Ekmekcioglu S, Zhang Y, Duan F, Yadav SS, Basu S, Allison J, Sharma P, Diab A. Phase II Clinical Trial to Assess the Safety and Efficacy of Tocilizumab in Combination with Ipilimumab and Nivolumab for Treatment-naïve Metastatic Melanoma. American College of Rheumatology Annual Meeting, 2023. e-Pub 2023.
3. Hennegan T, Burton EM, Simpson L, Prieto VG, Ross MI, Glitza IC, Beal LG, Gershenwald JE, Tawbi HA, Wong MK, Wang Z, Bassett RL, Lucci A, Lee JE, Fisher SB, Patel SP, McQuade JL, Davies MA, Wargo JA, Amaria RN. Expanded cohort and extended follow-up of neoadjuvant plus adjuvant (neo + adj) dabrafenib (D) and trametinib (T) in patients (pts) with surgically resectable stage (stg) III/IV melanoma. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
4. Morad G, Yang Y, Duncan S, Ferguson SD, Wargo JA, Burton EM, Tawbi HA, Davies MA, Liang H, Glitza IC. Longitudinal single-cell (sc) immune profiling of cerebrospinal fluid (CSF) from melanoma patients (pts) with leptomeningeal disease (LMD) treated with intrathecal (IT) and intravenous (IV) nivolumab (N). 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
5. Aggarwal, T, Reyes, S, Oliva G, IC. Thyroid Lymphoma in Hashimoto's Thyroiditis. ENDO Society Meeting 2023, 2023. e-Pub 2023.
6. Phillips S, Burton EM, Kreidieh FY, Glitza IC, McQuade JL, Amaria RN, Diab A, Patel SP, Wong MK, Li J, Chung C, Milton DR, Malke J, Simon J, Wefel JS, Davies MA, Tawbi HA. Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM). 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
7. Nelson BE, Roszik J, NOIA BARRETO CM, Nardo M, Ahmed J, Campbell E, Johnson A, Piha-Paul SA, Glitza IC, Weathers SS, Cabanillas ME, Javle MM, Meric-Bernstam F, Subbiah V. RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
8. Abdel-Wahab N, Johnson DH, Amaria RN, Montazari EJ, McVay KK, Spillson CA, S-E B, Oliva ICG, Patel S, Awiwi MO, Hassan A, Tahon N, Elsayes KM, Wong M, McQuade J, Tawbi H, Davies MA, Yee C, Ekmekcioglu S, Zhang Y, Duan F, Yadav SS, Basu S, Allison J, Sharma P, Diab A. Phase II Clinical Trial to Assess the Safety and Efficacy of Interleukin-6 Receptor Blocker in Combination with Ipilimumab and Nivolumab for Metastatic Melanoma. Seventh International Congress on Controversies in Rheumatology & Autoimmunity (CORA), 2023. e-Pub 2023.
9. Glitza IC, Saberian C, Simon J, Duncan S, Amaria R, Davies M, Diab A, Mcquade J, Patel S, Tawbi HA, Yee C, Wong M, McCutcheon I, Milton D, Ferguson S. Leptomeningeal disease (LMD) in patients (pts) with metastatic melanoma (MM): Survival analysis of a contemporary cohort. 2022 ESMO Congress, 2022. e-Pub 2022.
10. Ho JJ, Mattei J, Tetzlaff M, Williams M, Davies M, Diab A, Glitza IC, Mcquade J, Patel S, Tawbi HA, Wong M, Yee C, Fisher SB, Hanna EY, Keung EZ, Ross M, Su SY, Faria SC, Nagarajan P, Amaria R. Neoadjuvant checkpoint inhibitor immunotherapy (IMT) for resectable mucosal melanoma (MM). 2022 ESMO Congress, 2022. e-Pub 2022.
11. Abdel-Wahab N, Montazari EJ, Spillson C, Amaria R, Glitza IC, Patel S, Awiwi M, Hassan A, Tahon N, Elsayes KM, Altan M, Wong M, Mcquade J, Tawbi HA, Davies M, Yee C, Sharma P, Allison J, Johnson D, Diab A. Phase II clinical trial: Safety and efficacy study of tocilizumab (Toci) in combination with ipilimumab (Ipi) 3mg/kg plus nivolumab (Nivo) 1mg/kg in patients (pts) with metastatic melanoma (MM). Annals of Oncology, 2022. e-Pub 2022.
12. Abdel-Wahab N, Montazari E, Spillson C, Bentebibel S, Awiwi M, Gao J, Altan M, Wong MK, Glitza IC, Amaria RN, McQuade JL, Patel SP, Tawbi HA, Davies MA, Yee C, Sharma P, Allison JP, Ekmekcioglu S, Diab A, Elsayes KM. Tocilizumab in combination with ipilimumab and nivolumab in solid tumors. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
13. Abdel-Wahab N, Kus T, S-E B, McQuade JL, Glitza IC, Amaria RN, Patel SP, Wong MKK, Tawbi HA, Davies MA, Peterson SK, Shete S, Yee C, Kavelaars A, Suarez-Almazor ME, Diab A. Immune-related adverse events and symptom burden in patients with melanoma receiving adjuvant immune checkpoint inhibitor. J Clin Oncol, 2022. e-Pub 2022.
14. Bentebibel S, Johnson D, Amariae R, McGrail D, Lecagoonporn S, Haymaker C, Duose D, Wani K, Safa H, Glitza IC, Patel SP, Wong MK, Tawbi H, Burks J, Yang X, Hwu P, Yee C, Davies MA, Murthy R, Bernatchez C, Ekmekcioglu S, Diab A, Lizée G. Intratumoral CD40 agonist sotigalimab with pembrolizumab induces broad innate and adaptive immune activation in local and distant tumors in metastatic melanoma. Cancer Research 82(12), 2022. e-Pub 2022.
15. Dumbrava EE, Burton EM, Subudhi SK, Milton DR, Aparicio A, Yap TA, Naing A, Corn PG, Pilié PG, Zurita AJ, Wang J, Amaria RN, McQuade JL, Glitza IC, Lazar AJ, Meric-Bernstam F, Logothetis C, Davies MA, Hwu P, Tawbi HA. Phase I/II study of the selective PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
16. Abdel-Wahab N, Kus T, Bentebibel S, McQuade JL, Glitza IC, Amaria RN, Patel SP, Wong MK, Tawbi HA, Davies MA, Peterson SK, Shete S, Yee C, Kavelaars A, Suarez-Almazor ME, Diab A. Immune-related adverse events and symptom burden in patients with melanoma receiving adjuvant immune checkpoint inhibitor. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
17. Montazari EJ, Abdel-Wahab N, Johnson DH, Amaria RN, McVay KK, Spillson CA, S-E B, Glitza Oliva IC, Patel S, Awiwi MO, Hassan A, Tahon N, Elsayes KM, Altan M, Wong M, McQuade J, Tawbi H, Davies MA, Yee C, Ekmekcioglu S, Zhang Y, Duan F, Yadav SS, Basu S, Allison J, Sharma P, Diab A. Clinical outcome and preliminary immune analysis of phase II clinical trial of combination of tocilizumab with ipilimumab and nivolumab for patients with treatment naive metastatic melanoma. J IOTECH, 2022. e-Pub 2022.
18. Burton EM, Amaria RN, Glitza IC, Milton DR, Diab A, Patel SP, McQuade JL, Honaker V, Wong MKK, Hwu P, Wargo JA, Davies MA, Tawbi HAH. Phase II Study of TRIplet combination Nivolumab (N) with Dabrafenib (D) and Trametinib (T) (TRIDeNT) in patients (pts) with PD-1 naïve or refractory BRAF-mutated metastatic melanoma (MM) with or without active brain metastases. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
19. Hasanov M, Milton DR, Sirmans E, Saberian CM, Posada E, Gershenwald JE, Torres-Cabala CA, Huse JT, Tawbi HAH, Glitza IC, Li J, Chung C, Yeboa D, Opusunju S, Kim BYS, Lang FF, Haydu LE, Davies MA, Ferguson SD. Predictors of overall survival (OS) in patients (pts) with melanoma brain metastasis (MBM) in the modern era. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
20. Jeun R, Yedururi S, Lavis V, Best C, Varghese J, Dadu R, Glitza IC, Thosani S. Pancreatic volumes in immune checkpoint inhibitor-induced diabetes. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
21. Jackson N, Rodgers T, John I, Milton DR, Haydu LE, Amaria RN, Diab A, McQuade JL, Patel SP, Tawbi HAH, Wong MKK, Davies MA, Glitza IC. Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i). 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
22. Hasanov M, Milton DR, Patel SP, Tawbi HAH, Glitza IC, Ferguson SD, Ledesma DA, Torres-Cabala CA, Lazar AJ, Burton EM, Gershenwald JE, Haydu LE, Davies MA. Incidence, timing, and predictors of CNS metastasis in patients (Pts) with clinically localized cutaneous melanoma (CM). 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
23. Amaria RN, Postow MA, Tetzlaff MT, Ross MI, Glitza IC, McQuade JL, Wong MKK, Gershenwald JE, Goepfert R, Keung EZY, Fisher SB, Milton DR, Patel SP, Diab A, Simpson L, Davies MA, Wargo JA, Burton EM, Ariyan CE, Tawbi HAH. Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
24. Patel SP, Hwu P, Davies M, Wong M, Tawbi H, Amaria R, Diab A, Gombos D, Glitza IC. Characteristics of uveal melanoma patients with central nervous system metastases. Cancer Research 80(19), 2020. e-Pub 2020.
25. Shephard MP, Glover M, Balmes G, Cain S, Vardeleon A, Mouton R, Posada L, Simien R, Hwu P, Davies M, Yee C, Wong M, Tawbi H, Woodman S, Amaria R, Diab A, Glitza I, Hwu W, Patel S. Clinical characteristics of responders to nivolumab plus ipilimumab (Nivo/Ipi) in metastatic uveal melanoma. Cancer Research 80(19), 2020. e-Pub 2020.
26. Glitza IC, Patel S, Zarifa A, Leung CH, Lin H, McQuinn L, Gong J, Yilmaz B, Chambers J, Sulovic S, John I, Hennegan T, Fu S, Tsimberidou AM, Janku F, Karp DD, Meric-Bernstam F, Naing A. Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience. 2020 ESMO Virtual Congress, 2020. e-Pub 2020.
27. Colen RR, Ologun GO, Zinn P, AK M, Arora R, Burton EM, Glitza IC, Tawbi HAH, Patel SP, Diab A, Wong MKK, McQuade JL, Ross MI, Ahmed S, Elshafeey N, Gershenwald JE, Davies MA, Tetzlaff MT, Amaria RN, Wargo JA. Radiomic signatures to predict response to targeted therapy and immune checkpoint blockade in melanoma patients (pts) on neoadjuvant therapy. 2020 ASCO Virtual Scientific Program, 2020. e-Pub 2020.
28. Glitza IC, Phillips S, Brown C, Haymaker CL, Bassett RL, Lee JJ, Rohlfs ML, Richard J, Iqbal M, McCutcheon IE, Ferguson SD, Heimberger AB, O'Brien BJ, Tummala S, Thakurta NG, Debnam M, Burton EM, Tawbi HAH, Davies MA. Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). 2020 ASCO Virtual Scientific Program, 2020. e-Pub 2020.
29. Lutzky J, Holbrook K, Amin A, Davis JM, Davies MA, Diab A, Glitza IC, Amaria RN, Patel S, Tawbi HA. Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis. 2019 ESMO Congress, 2019. e-Pub 2019.
30. Burton EM, Glitza IC, Mahoney J, Wortman J, Aunis J, Litcofsky K, Cook D, Jayaraman L, Ibrahim RA, LaVallee T, Tawbi HAH, Wargo JA. Stool donor qualification and collection from metastatic melanoma (MM) patients (pts) who have responded to checkpoint inhibitors (CPI) for manufacturing of fecal microbiota transplantation (FMT). 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, 2019. e-Pub 2019.
31. Glitza IC. Hypertrophic lichenoid dermatitis immune-related adverse event from combined immune checkpoint and exportin inhibitor therapy: A histologic diagnostic pitfall for superficially invasive squamous cell carcinoma. ASDP Meeting 2019, 2019. e-Pub 2019.
32. Burton E, Woody T, Glitza IC, Amaria RN, Keung E, Diab A, Patel S, Wong MK, Yee C, Hwu P, McQuade J, Woodman S, Tetzlaff M, Davies M, Wargo J, Rai K, Tawbi H. A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM). ASCO Annual Meeting 2019, 2019. e-Pub 2019.
33. Burton EM, Woody T, Glitza IC, Amaria RN, Keung EZY, Diab A, Patel SP, Wong MKK, Yee C, Hwu P, McQuade JL, Woodman SE, Tetzlaff MT, Davies MA, Wargo JA, Rai K, Tawbi HAH. A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM). 2019 ASCO Annual Meeting, 2019. e-Pub 2019.
34. Amaria RN, Haymaker CL, Forget MA, Bassett R, Cormier JN, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Royal RE, Ross MI, Tawbi HAH, Wargo JA, Wong MKK, Bernatchez C, Hwu P. Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM). 2019 ASCO Annual Meeting, 2019. e-Pub 2019.
35. Sprouse ML, Welte T, Boral D, Liu HN, Yin W, Vishnoi M, Goswami-Sewell D, Li L, Pei G, Jia P, Glitza IC, Marchetti D. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling. International Journal of Molecular Sciences. e-Pub 2019.
36. Spencer C, Gopalakrishnan V, McQuade J, Andrews M, Helmink B, Khan MA, Sirmans E, Haydu L, Cogdill A, Burton E, Amaria R, Patel S, Glitza IC, Davies MA, Posada E, Hwu WJ, Diab A, Nelson K, Tawbi H, Wong M, Jenq R, Cohen L, Daniel-Macdougall C, Wargo J. The gut microbiome of melanoma patients is distinct from healthy controls, and associations with treatment outcomes are influenced by host lifestyle factors. AACR Annual Meeting 2019, 2019. e-Pub 2019.
37. Gopalakrishnan V, Andrews M, Chen WS, Spencer C, Vence L, Reuben A, Cooper Z, Prieto P, Tetzaff M, Khan MA, Lazar A, Hudgens C, Haydu L, Tawbi H, Hwu P, Hwu WJ, Amaria R, Burton E, Woodman S, Diab A, Patel S, Glitza IC, Zhang J, Petrosino J, Jenq R, Davies MA, Gershenwald J, Sharma P, Allison J, Futreal A, Wargo JA. Therapeutic efficacy and tolerability of combined immune check-point blockade in metastatic melanoma patients is influenced by the gut microbiome. AACR Annual Meeting 2019, 2019. e-Pub 2019.
38. Helmink B, Gopalakrishnan V, Khan A, Gaudreau PO, Sirmans E, Burton E, Jensen V, Duran A, Martin L, Harris A, Miles A, McQuade J, Cogdill A, Spencer C, Arora R, Ajami N, Petrosino J, Mohamed J, Patel S, Wong M, Amaria R, Gershenwald J, Hwu P, Hwu WJ, Davies M, Glitza IC, Tawbi H, Marnellos G, Sceneay J, Wortman J, Jayaraman L, Cook D, LaValle T, Jenq R, Heffernan T, Wargo J. Variation of the gut microbiome of complete responders to immune checkpoint blockade and healthy individuals- implications for clinical trial design. SITC 2018, 2018. e-Pub 2018.
39. Bentebibel S, Johnson D, Lecagoonporn S, Haymaker C, Safa H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies M, Wong M, Hwu WJ, Hwu P, Overwijk W, Trifan O, Bernatchez C, Diab A. Phase 1/2 study of image guided intratumoral CD40 agonistic monoclonal antibody (APX005M) in combination with systemic pembrolizumab for treatment-naive metastatic melanoma. SITC 2018, 2018. e-Pub 2018.
40. Gopalakrishnan V, Spencer C, McQuade J, Andrews M, Helmink B, Cogdill A, Sirmans E, Haydu L, Posada E, Burton E, Glitza IC, Amaria R, Patel S, Diab A, Wong M, Tawbi H, Hwu WJ, Davies M, Hwu P, Jeng R, Nelson K, Daniel-MacDougall C, Cohen L, Wargo J. The gut microbiome of metastatic melanoma patients initiating systemic therapy is influenced by host factors including diet, probiotic and antibiotic use. SITC 2018, 2018. e-Pub 2018.
41. Glitza IC, Rohlfs ML, Iqbal M, Richard J, Burton E, Duncan S, Brown C, Anderson J, Hwu P, Hwu WJ, Yee C, Patel S, Woodman S, Amaria R, Diab A, Tawbi H, Davies M. A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (NIVO) for melanoma patients (pts) with Leptomeningeal disease (LMD). Annals of Oncology 29(8), 2018. e-Pub 2018.
42. McQuade JL, Gopalakrishnan V, Spencer C, Andrews MC, Helmink B, Cogdill AP, Sirmans E, Haydu L, Posada E, Burton E Glitza IC, Amaria R, Patel S, Diab A, Wong M, Tawbi H, Hwu WJ, Davies MA, Hwu P, Jenq R, Nelson K, Daniel CR, Cohen L, Wargo J. The gut microbiome of melanoma patients is distinct from that of health individuals and is impacted by probiotic and antibiotic use. Melanoma Congress 2018 _SMR, 2018. e-Pub 2018.
43. Vishnoi M, Boral D, Liu HN, Sprouse ML, Yin W, Davies MA, Glitza Oliva IC, Marchetti D. Targeting USP7/PTEN axis regulates the metastatic competency of bone marrow-resident melanoma cells. Cancer Research 78(13), 2018. e-Pub 2018.
44. Tawbi HAH, Amaria RN, Glitza IC, Milton D, Hwu WJ, Patel SP, Wong MKK, Yee C, Woodman SE, McQuade JL, Hwu P, Perdon KM, Shephard M, Burton EM, Wargo JA, Davies MA. Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM). 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
45. Schvartsman G, Ma J, Bassett RL, Haydu LE, Amaria RN, Hwu P, Hwu WJ, Patel SP, Wong MKK, Woodman SE, Davies MA, Glitza IC, Tawbi HAH. Outcomes of metastatic melanoma (MM) patients (pts) after discontinuation of anti-Programmed-Death 1 (PD1) therapy without disease progression. 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
46. Johnson DH, Bentebibel S, Lecagooporn S, Bernatchez C, Haymaker C, Murthy R, Tam A, Yee C, Amaria R, Patel SP, Tawbi H, Glitza IC, Davies MA, Hwu WJ, Hwu P, Overwijk W, Diab A. Phase I/II dose escalation and expansion cohort safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab for treatment naive metastatic melanoma. e-Pub 2018.
47. Schvartsman G, Glitza IC, Milton D, Amaria R, Hwu P, Hwu WJ, Diab A, Wong MK, Patel SP, Wefel JS, Burton EM, Brown C, Woodman SE, Beosch IM, Chung C, Davies MA, Tawbi H. A phase II study of bevacizumab (BEV) in combination with atezolizumab (ATEZO) in pts (PTS) with untreated melanoma brain metastases (BEAT-MBM). e-Pub 2018.
48. Amaria R, Reddy S, Tawbi H, Davies MA, Ross M, Glitza IC, Cormier J, Lewis C, Hwu WJ, Ehab YH, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai S, Ehlers R, Burton EM, Tetzlaff MT, Wargo JA. Neoadjuvant (neo) immune checkpoint blockade (ICB) in patients (Pts) with high-risk resectable metastatic melanoma (MM). e-Pub 2018.
49. Tawbi H, Peng W, Milton D, Amaria R, Glitza IC, Hwu WJ, Patel SP, Wong MK, Woodman SE, Yee C, McQuade JL, Tetzlaff MT, Lazar AJ, Cain S, Burton EM, Beumer JH, Hwu P, Davies MA. Phase I/II study of the P13K inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss. e-Pub 2018.
50. Glitza IC, Schvartsman G, Tawbi H. Advances in the systemic treatment of melanoma brain metastases. ESMO 2018 Annals of Oncology, 2018. e-Pub 2018.
51. Keung EZ, Glitza IC, Burton E, Amaria RN, Patel SP, Diab A, Yee C, Wong MK, Hwu WJ, Hwu P, Woodman SE, Tetzlaff MT, Trujillo-Conley N, Milton DR, Davies MA, Rai K, Fernandez I, Blanco JM, Vence LM, Sharma P, Allison JP, Wargo JA, Tawbi H. The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on the immune infiltrate in metastatic melanoma (MM). AACR Annual Meeting 2018, 2018. e-Pub 2018.
52. Scutti JA, Vence LM, Royal RE, Wray TC, Cormier JN, Lee JE, Lucci A, Gershenwald JE, Ross MI, Wargo JA, Millerchip K, Amaria RN, Davies MA, Diab A, Glitza IC, Hwu WJ, Patel S, Woodman SE, Overwijk WE, Hwu P. Resiquimod, a toll like receptor agonist promotes melanoma regression by enhancing plasmacytoid dendritic cells and T cytotoxic activity as a vaccination adjuvant and by direct tumor application. AACR Annual Meeting, 2018. e-Pub 2018.
53. Amaria RN, Trinh V, Gu J, McIntyre S, Torres C, Simien R, Diab A, Tawbi H, Davies MA, Wong MK, Hwu P, Glitza IC, Patel SP, Hwu WJ. Treatment strategies using anti-PD1\PD-L1 (anti-PD) and BRAF/MEK inhibitor (BRAFi) therapy: a retrospective study comparing sequential vs. concurrent administration in BRAF-mutated metastatic melanoma (BMMM). AACR Annual Meeting 2018, 2018. e-Pub 2018.
54. Johnson D, Lecagoonporn S, Bernatchez C, Haymaker C, Bentebibel S, Uemura M, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies M, Wong M, Hwu WJ, Hwu P, Overwijk W, Diab A. Phase I/II safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab in metastatic melanoma patients. SITC 2017. e-Pub 2017.
55. Haymaker C, Uemura M, Hwu WJ, Murthy R, James M, Bhatta A, Bentebibel S, Brevard J, Geib J, Lipford K, Cornfeld M, Chunduru S, Yee C, Woodman S, Amaria R, Patel S, Tawbi H, Glitza IC, Davies M, Overwijk W, Hwu P, Bernatchez C, Diab A. TLR9 agonist harnesses innate immunity to drive tumor-infiltrating T cell expansion in distant lesions in a phase 1/2 study of intratumoral IMO-2125+ipilimumab in anti-PD1 refractory melanoma patients. SITC 2017. e-Pub 2017.
56. Johnson D, Zobniw C, Trinh V, Bassett R, Ma J, Anderson J, Davis J, Joseph J, Uemura M, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies M, Wong M, Woodman S, Hwu P, Hwu WJ, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared to corticosteroids alone for management of immune related enterocolitis. SITC 2017. e-Pub 2017.
57. Haydu L, Gershenwald J, Glitza IC, Amaria R, Lazar A, Prieto V, Tawbi H, Tetzlaff M, Wargo J, Davies M. Refining risk models for distant and CNS metastasis in Stage III melanoma. SMR 2017. e-Pub 2017.
58. Andrews M, Chen W, Spencer C, Gopalakrishnan V, Tawbi H, Lazar A, Tetzlaff M, Patel S, Hwu P, Hwu WJ, Diab A, Glitza IC, Amaria R, Burton E, Woodman S, Davies M, Gershenwald J, Sharma P, Allison J, Futreal A, Wargo J. Molecular, immune and microbial predictors of response and toxicity to combination immune checkpoint blockade (CICB) in melanoma (MEL) patients. SMR 2017. e-Pub 2017.
59. Amaria R, Haymaker C, Forget M, Bernatchez C, Patel V, Carpio D, Patel S, Hwu WJ, Wong M, Davies M, Diab A, Glitza IC, Tawbi H, Hwu P. TGF-B Dominant Negative Receptor (TGF-DNRII) and NGFR-transduced tumor infiltrating lymphocytes (TIL) and high dose interleukin-2 (IL-2) in patients (pts) with metastatic melanoma (MM). SMR 2017. e-Pub 2017.
60. Reddy S, Amaria R, Spencer C, Tetzlaff M, Reuben A, Andrews M, Wang L, Woodman S, Zhu H, Blando J, Vence L, Zhang S, Jiang H, Gopalakrishnan V, Hudgens C, Wani K, Tawbi H, Diab A, Glitza IC, Patel S, Hwu WJ, Wong M, Hwu P, Cormier J, Lucci A, Royal R, Lee J, Simpson L, Burton E, Gershenwald J, Ross M, Allison J, Sharma P, Davies M, Wargo J. Neoadjuvant nivolumab versus combination ipilumumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage II and oligometastatic stage IV melanoma: preliminary findings. SITC 2017. e-Pub 2017.
61. Diab A, Haymaker C, Uemura M, Murthy R, James M, Geib J, Cornfeld M, Swann S, Yee C, Wargo J, Amaria R, Patel S, Tawbi H, Glitza IC, Woodman S, Hwu WJ, Davies M, Overwijk W, Bernatchez C, Hwu P. A phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1- refractory melanoma. ESMO 2017. e-Pub 2017.
62. Glitza IC, Ma J, Ferguson S, Bassett R, Haydu L, Davies M. Characteristics of metastatic melanoma (MM) patients with leptomeningeal disease (LMD) and survival of > 1 year. ESMO 2017. e-Pub 2017.
63. Woodman SE, Prieto P, Andrews MC, Amaria RN, Tetzlaff M, Diab A, Patel SP, Wen-Jen H, Glitza I, Tawbi H, Hwu P, Cormier J, Lucci A, Royal R, Lee J, Bassett R, Simpson L, Burton E, Zhao L, Grimm E, Reuben A, Spencer C, Oba J, Ross M, Gershenwald J, Davies M, Wargo JA. Novel neoadjuvant targeted therapy trial yields insight into molecular mechanisms of response. Cancer Research 77(13), 2017. e-Pub 2017.
64. McKean M, Haydu L, Ma J, Bassett R, Hwu WJ, Patel S, Diab A, Glitza IC, Tawbi H, Wong M, McQuade J, Hwu P, Davies M, Amaria R. Prognostic factors for overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with immune checkpoint inhibitors: A single institution study of 696 pts. ASCO 2017. e-Pub 2017.
65. Wargo J, Amaria R, Prieto P, Andrews M, Tetzlaff M, Futreal A, Hwu P, Hwu WJ, Glitza IC, Tawbi H, Cormier J, Lee J, Patel S, Simpson L, Burton E, Bassett R, Ross M, Gershenwald J, Davies M, Woodman S. Relapse-free survival and target identification to enhance response with neoadjuvant and adjuvant debrafenib+trametinib (D+T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma. ASCO 2017. e-Pub 2017.
66. Royal R, Vence L, Wray T, Cormier J, Lee J, Gershenwald J, Ross M, Wargo J, Amaria R, Davies M, Diab A, Glitza IC, Hwu WJ, Patel S, Woodman S, Overwijk W, Hwu P. A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application. ASCO 2017. e-Pub 2017.
67. Pires Da Silva I, Johnpulle R, Banks P, Grass G, Smith J, Ashlyn E, Goldinger S, Roberts-Thomson R, Millward M, Glitza IC, Haydu L, Atkinson V, Wang T, Eroglu Z, Conry R, Shackleton M, Hong A, Long G, Johnson D, Menxies A. Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1). ASCO 2017. e-Pub 2017.
68. Keung E, Burton E, Amaria R, Glitza IC, Patel S, Diab A, Yee C, Wong M, Hwu WJ, Hwu P, Woodman S, Tetzlaff M, Milton D, Perez K, Davies M, Rai K, Wargo J, Tawbi H. A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients with metastatic melanoma (MM). ASCO 2017. e-Pub 2017.
69. Wargo J, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, Andrews M, Tetzlaff M, Lazar A, Hwu P, Hwu WJ, Glitza IC, Tawbi H, Patel S, Lee J, Davies M, Gershenwald J, Futreal A, Sharma P, Allison J, Jeng R. Association of the diversity and composition of the gut microbiome with responses and survival in metastatic melanoma patients on anti-PD-1 therapy. ASCO 2017. e-Pub 2017.
70. Schvartsman G, Ma J, Bassett R, Haydu L, Amaria R, Hwu P, Hwu WJ, Diab A, Patel S, Davies M, Wabi H, Glitza IC. Incidence, patterns of progression and outcomes of melanoma brain metastasis (MBM) during programmed-death 1 inhibitor (PD1i) therapy. ASCO 2017. e-Pub 2017.
71. Patel S, Glitza IC, Diab A, Amaria R, Davies M, Hwu P, Tawbi H, Hwu WJ. The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with uveal melanoma (UM). ASCO 2017. e-Pub 2017.
72. Chen W, Andrews M, Spencer C, Tawbi H, Lazar A, Tetzlaff M, Patel S, Hwu P, Hwu WJ, Diab A, Glitza IC, Amaria R, Burton E, Woodman S, Davies M, Gershenwald J, Sharma P, Allison J, Futreal A, Wargo J. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). ASCO 2017. e-Pub 2017.
73. Wargo JA, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, Andrews MC, Tetzlaff MT, Lazar A, Hwu P, Hwu WJ, Glitza IC, Tawbi HAH, Patel SP, Lee JE, Davies MA, Gershenwald JE, Futreal A, Sharma P, Allison JP, Jenq RR. Association of the diversity and composition of the gut microbiome with responses and survival in metastatic melanoma patients on anti-PD-1 therapy. 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
74. Chen WS, Andrews MC, Spencer C, Tawbi HAH, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, Davies MA, Gershenwald JE, Sharma P, Allison JP, Futreal A, Wargo JA. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
75. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Pl C, Beird HC, Garber HC, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria R, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm E, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma, 2017. e-Pub 2017.
76. Vishnoi M, Liu H, Boral D, Yin W, Sprouse M, Thiery J, Glitza IC, Marchetti D. Translating CTCs for clinical use: melanoma patient-derived CTCs evolution in xenografts. AACR 2017. e-Pub 2017.
77. Haymaker C, Uemura M, Murthy R, James M, Wang D, Brevard J, Swann S, Geib J, Cornfeld M, Chunduru S, Agrawal S, Yee C, Wargo J, Amaria R, Patel S, Tawbi H, Glitza IC, Woodman S, Hwu WJ, Davies M, Hwu P, Overwijk W, Bernatchez C, Diab A. Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma. AACR 2017. e-Pub 2017.
78. Glitza IC, Tawbi H, Davies MA. Melanoma Brain Metastases: Current Areas of Investigation and Future Directions. Cancer Journal, 2017. e-Pub 2017.
79. Uemura MI, Haymaker CL, Murthy R, James M, Cornfeld M, Chunduru S, Agrawal S, Yee C, Wargo JA, Amaria RN, Patel SP, Tawbi HA, Glitza IC, Woodman SE, Hwu W, Davies MA, Hwu P, Overwijk WW, Bernatchez C, Diab A. Intratumoral IMO-2125, a TLR9 agonist in combination with ipilimumab in PD-L1 refractory melanoma. e-Pub 2017.
80. Uemura M, Haymaker C, Murthy R, James M, Cornfeld M, Chunduru S, Agrawal S, Yee C, Wargo J, Amaria R, Patel S, Tawbi H, Glitza IC, Woodman S, Hwu WJ, Davies M, Hwu P, Overwijk W, Bernatchez C, Diab A. Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM). ASCO 2017. e-Pub 2016.
81. Amaria RN, Haymaker CL, Bernatchez C, Forget M, Patel V, Hwu W, Davies MA, Patel SP, Diab A, Glitza IC, Tawbi HA, Woodman SE, Wargo JA, Ross MI, Lee JE, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Hwu P. A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM). ASCO Annual Meeting, 2016. e-Pub 2016.
82. Rohlfs M, Bassett RL, Lacey C, McQuail N, Mehta U, John I, Simien R, Tupue S, Dett TK, Glitza IC, Diab A, Amaria RN, Tawbi HA, Davies MA, Hwu W, Hwu P, Patel SP. BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma. 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
83. Barcena E, Trinh V, McIntyre SE, Simien R, Cain S, Diab A, Amaria RN, Patel SP, Glitza IC, Tawbi HA, Davies MA, Hwu W. Responses in patients with BRAF V600-mutant metastatic melanoma receiving anti-PD1/PDL1 therapy alone or combined with BRAF inhibitors. ASCO 2016, 2016. e-Pub 2016.
84. Kim DW, Haymaker C, McQuail N, Sirmans E, Spencer C, Glitza IC, Amaria R, Woodman S, Patel S, Davies M, Yee C, Hwu W, Bernatchez C, Wargo J, Sharma P, Allison J, Hwu P, Tam A, Diab A. Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM). Journal for ImmunoTherapy of Cancer 2015, 2016. e-Pub 2016.
85. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff M, Xu C, McKenzie J, Zhang C, Liang X, Williams L, Deng W, Chen G, Mbofung R, Lazar A, Torres-Cabala C, Cooper Z, Chen P, Tieu T, Spranger S, Yu X, Bernatchez C, Forget M, Haymaker C, Amaria R, McQuade J, Glitza IC, Cascone T, Li H, Kwong L, Heffernan T, Hu J, Bassett R, Bosenberg M, Woodman S, Overwijk W, Lizée G, Roszik J, Gajewski T, Wargo J, Gershenwald J, Radvanyi L, Davies M, Hwu P. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. AACR Annual Meeting 2016, 2016. e-Pub 2016.
86. Shaw AC, Trinh V, Bassett RL, Glitza IC, Diab A, Amaria RN, Tawbi HA, Davies MA, Hwu W, Hwu P, Patel SP. Retrospective analysis of safety and efficacy of ipilimumab in elderly patients with advanced melanoma. 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
87. Kim DW, Haymaker C, McQuail N, Sirmans E, Spencer C, Glitza IC, Amaria R, Woodman S, Patel S, Davies MA, Yee C, Hwu WJ, Bernatchez C, Wargo JA, Sharma P, Allison J, Hwu P, Tam A, Diab A. Pilot Study of intratumoral cryoablation in combination with systemic checkpoint blockade in patients with metastatic melanoma, 2015. e-Pub 2015.
88. Kim DW, Haymaker C, Perdon K, Amaria R, McQuail N, Fa'ak F, Spencer CN, Sirmans E, Glitza IC, Wargo JA, Woodman S, Patel S, Davies M, Hwu WJ, Bernatchez C, Hwu P, Diab A. Phase II trial of nab-paclitaxel (ABI) plus ipilimumab (ipi) in patients with metastatic melanoma (MM). Society for Melanoma Research. e-Pub 2015.
89. McQuade J, Guo C, Panka D, Reuben A, Bassett R, a J, Lazar A, Tetzlaff M, Simpson L, Mouton R, Glitza IC, Patel S, Hwu WJ, Amara R, Diab A, Hwu P, Wargo JA, Sullivan R, Kim K, Davies M. Phase II study of dabrafenib (D) and trametinib (T) following progression on BRAF inhibitor (BRAFi): clinical and molecular predictors of response. Society for Melanoma Research, 2015. e-Pub 2015.
90. ML Rohlfs GI, Jr R, John I, Richard J, Iqbal M, Bernzen T, Gerber DL, Lacey C, Diab A, Amaria RN, Woodman SE, Patel SP, Yee C, Hwu WJ, Hwu P, Papadopoulos N, Davies MA. Long-term efficacy of intrathecal interleukin‐2 (IT IL2) in metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). ESMO 2015, 2015. e-Pub 2015.
91. Amaria RN, Wargo JA, Cooper ZA, Tetzlaff MT, Reuben A, Davies MA, Gershenwald JE, Jiang H, Austin-Breneman J, Lee JE, Hwu P, Hwu W, Cormier JN, Royal RE, Lucci A, Patel SP, Diab A, Glitza IC, Burton EM, Ross MI. Treatment with neoadjuvant BRAF Inhibition Yields Responses in Patients (pts) with High Risk Borderline Resectable Stage III Melanoma. ASCO 2015, 2015. e-Pub 2015.
92. Sakamuri D, Betancourt Cuellar SL, Glitza IC, Fu S, Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Subbiah V, Fanale MA, Cabanillas ME, Meric-Bernstam F, Janku F. Phase I study: Ipilimumab (anti CTLA-4) in combination with Lenalidomide in patients with advanced cancers, 2015. e-Pub 2015.
93. Patel SP, Lam S, Rohlfs ML, Fox PS, Richard J, Iqbal M, Bernzen T, Glitza IC, Papadopoulos NE, Hwu P, Davies MA. BRAF and NRAS mutations in Metastatic Melanoma Patients with Leptomeningeal Disease. ASCO Annual Meeting 2015, 2015. e-Pub 2015.
94. McQuade JL, Chen G, Panka DJ, Reuben A, Bassett RL, Joon A, F Lazar AJ, Tetzlaff MT, Simpson L, Mouton R, Patel SP, Glitza IC, Hwu W, Amaria RN, Diab A, Hwu P, Wargo JA, Sullivan RJ, Kim K, Davies MA. Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular predictors of response. ASCO, 2015. e-Pub 2015.
95. Amaria RN, Bassett RL, Simpson L, Delaney F, Hwu P, Kim K, Hwu W, Patel SP, Glitza IC, Davies MA, Woodman SE, Yee C, Bedikian AY. Phase I study of ipilimumab (IPI) with biochemotherapy (BCT) for chemonaïve patients with metastatic melanoma (MM). ASCO 2015, 2015. e-Pub 2015.
96. Wargo JA, Amaria RN, Ross MI, Saw RP, Gershenwald JE, Hwu P, Patel SP, Glitza IC, Diab A, Kefford R, Scolyer RA, Rizos H, Thompson JF, Shannon K, Spillane A, Carlino MS, Guminski A, Simpson L, Davies MA, Lon GV. Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma. ASCO 2015, 2015. e-Pub 2015.
97. Chakravarti N, Glitza IC, Trinh VA, Bassett RL, Hwu WJ, Prieto VG. Biomarker analysis predicts antitumor activity of Ipilimumab therapy in patients with refractory metastatic melanoma. Cancer Research(74), 2014. e-Pub 2014.
98. Glitza IC, Bernatchez C, Bassett RL, Vaugh C, Velasquez P, Diab A, Amaria RN, Yee C, Wood SE, Patel SP, Kim K, Davis MA, Papadopoulos NE, Bedikian AY, Hwu WJ, Radvanyi LG, Hwu P. Treatment with tumor-infiltrating lymphocytes (TIL) in metastatic melanoma and clinical benefit regardless of site of origin, mutation status, or prior checkpoint blockade. Journal of Clinical Oncology 32(5s), 2014. e-Pub 2014.
99. Hui D, Glitza I, Chisholm G, Yennu S, Bruera E. Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials. Cancer 119(5):1098-105, 2013. e-Pub 2013.
100. Glitza IC, Conter HJ, Turner R, Reddy S, Bruera E. Opinions of Nurses on the application and implications of DNR/DNI orders. ESMO 23(Supplement 9), 2012. e-Pub 2012.
101. Rodabe N. Amaria, Hussein A. Tawbi, Alexandra Ikeguchi, Glitza Oliva IC, Jennifer L McQuade, Michael A. Davies, Youlia Petrova, Cara Haymaker, Chantale Bernatchez, Marie-Andrée Forget, Karrie Wong, Erica Tobin, Micah J. Benson, Anna Truppel-Hartmann, Patricia M. Harris. Results of first-in-human, Phase 1 study of KSQ-001EX, an autologous tumor infiltrating lymphocyte therapy engineered to inactivate the SOCS1 gene, in patients with select advanced solid tumors. AACR 2026.
102. Glitza Oliva IC. A Machine Learning Approach to Optimal Lesion Selection for Tumor Infiltrating Lymphocyte (TIL) Harvest in Advanced Melanoma. SIO 2026 Annual Scientific Meeting.

Book Chapters

1. Piña, Y, Aaroe, AE, Forsyth, P, Gatewood, TS, Glitza, IC. Intrathecal treatments for leptomeningeal metastases, 331-361, 2022.
2. Glitza Oliva IC, Epner DE. Sticking by My Patients, No Matter What. In: Empathy: Real Stories to Inspire and Enlighten Busy Clinicians. McGraw Hill LLC, 2022.
3. Moyers JT, Glitza Oliva IC. Immunotherapy for Melanoma. In: Adv Exp Med Biol. 2nd Edition. Springer Nature, 81-111, 2021.
4. Albittar, A, Alhalabi, O, Glitza, IC. Immunotherapy for Melanoma, 51-68, 2020.
5. Glitza IC, Goff SL, Ross M, Margolin K. And Now for Something Completely Different: Immunotherapy Beyond Checkpoints in Melanoma. In: Am Soc Clin Oncol Educ Book, 1-12, 2020.
6. Glitza, IC, Heimberger, AB, Sulman, EP, Davies, MA. Prognostic Factors for Survival in Melanoma Patients with Brain Metastases, 267-297, 2016.
7. Glitza IC, Kim DW, Chae YK, Kim KB. Targeted Therapy in Melanoma. In: Cancer Genetics. Springer, 2016.
8. Glitza IC, Amy H, Erik S, Davies MA. Prognostic Factors for Survival in Melanoma Patients with Brain Metastases. In: Brain Metastases from Primary Tumors, 2016.
9. Glitza, IC, Varadhachary, GR. Carcinoma of Unknown Primary (CUP), 815-821, 2014.
10. Glitza IC, Varadhachary GR. Special Issues in Hematology and Oncology. In: Cancer Consult: Expertise for Clinical Practice. Wiley-Blackwell, 817-821, 2014.
11. Berger, JR, Glitza, IC. Von Economo’s encephalitis, 523-541, 2003.
12. Berger JR, Glitza IC. In: Clinical Neurovirology. Marcel Dekker, Inc, 2003.

Letters to the Editor

1. Nelson, BE, Roszik, J, Ahmed, J, Barretto, CN, Nardo, M, Campbell, E, Johnson, A, Piha-Paul, SA, Glitza, IC, Weathers, S, Cabanillas, ME, Javle, M, Meric-Bernstam, F, Subbiah, V. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers. Molecular cancer 23, 2024.
2. Glitza IC, Ferguson SD, Guha-Thakurta N. Rapid resolution of leptomeningeal disease with targeted therapy in a metastatic melanoma patient. J Neurooncol 133: 663-665, 2017.